MedTrace Logo

PsilOCD: A Pharmacological-Challenge Feasibility Study

NCT06258031 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-11-06

No results posted yet for this study

Summary

The purpose of this study is to assess the impact of psilocybin on cognitive inflexibility and neural plasticity in a cohort of people with obsessive-compulsive disorder (OCD).

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Psilocybin (COMP360)

Up to 10mg on two occasions

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Professor David Nutt · Imperial College London

  • Dr David Erritzoe · Imperial College London

  • Dr Luca Pellegrini · University of Hertfordshire/Imperial College London

  • Professor Naomi Fineberg · University of Hertfordshire

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-28
Primary Completion
2024-06-28
Completion
2024-07-24
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06258031 on ClinicalTrials.gov